Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%

However, Halozyme has clarified that its EPS guidance does not consider the impact of potential future share repurchases. Year to date, shares of HALO have rallied 39.2% against the industry's 3.8% decline. In the past 30 days, the Zacks Consensus Estimate for ALX Oncology's 2024 loss per share has narrowed from $3.33 to$2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to$2.73. Year to date, shares of ALXO have plunged 37.7%. Halozyme Therapeutics' (HALO ...